Breath Diagnostics, Inc. (BDx) firmly believes that there is an urgent and profound need for a low-cost, more-accurate, noninvasive technology to mitigate the effects of the lung cancer epidemic.  This technology will greatly benefit lung cancer patients, physicians and insurers.  Strategic investments will enable BDx to bring the OneBreath™ technology to the marketplace and thus help millions of cancer patients in the US and worldwide.

BDx aims to be the preeminent leader in breath analysis worldwide.  To this effect, BDx is seeking partners in the US, Europe, and China to develop and commercialize the OneBreath™ technology.

For more information please contact Brian Ennis –